Alcresta Infused With $10M Series B To Get First Product To Market
This article was originally published in The Pink Sheet Daily
Executive Summary
The Massachusetts nutritionals company has guaranteed it can transition from a development company to a commercial company without the help of a partner due to a recent infusion of cash but hopes to strike partnerships for certain indications and regions once the product gets to market.
You may also be interested in...
Alcresta Launches With Dynamic Business Model; Raises $10M Series A
Former Alnara executives have come together with the company’s previous investors to launch two start-ups focusing on enzyme therapies.
Alnara Execs Start Anew With Allena; $15 M Series A
Former Alnara founders Alexey Margolin and Robert Gallotto have begun a new venture that includes Alnara’s previous investors.
Lilly To Buy Alnara And Its Non-Porcine Pancreatic Enzyme Replacement Therapy
Alnara hopes to leverage Lilly's prior success with recombinant insulin products.